 reuters    shares of u s  pharmaceutical and biotechnology companies fell on tuesday after president donald trump said he was working on a  new system  to reduce prices in the industry  without providing details of his plan  trump s comments came as he backed a republican bill to repeal and replace the affordable care act  known as obamacare   i am working on a new system where there will be competition in the drug industry   trump tweeted   pricing for the american people will come way down   pharmaceutical and biotech shares fell broadly after trump s tweet  but had pared back steeper initial losses by afternoon trading  shares of pfizer inc  pfe n  and merck   co  mrk n  were down about   percent  while eli lilly   co  lly n  dropped   percent  the nasdaq biotechnology index  nbi was   percent lower  pausing momentum for the index  which has climbed about  percent this year after a brutal    i m skeptical about what it is that he might do that would actually have a material impact on drug prices   said paul heldman  managing partner at heldman simpson partners  which follows healthcare issues for institutional investors out of washington   i wouldn t rule it out  but i m just not there yet that he has some sort of broad plan that has a big impact in the marketplace that will actually become law   heldman said  u s  representative elijah cummings  the top democrat on the house of representatives committee on oversight and government reform  said he would meet with trump on wednesday to discuss efforts to lower prescription drug prices  trump has long vowed to repeal and replace obamacare  the house republicans  legislation would eliminate the requirement that most americans obtain medical insurance and create a system of tax credits to encourage people to purchase private insurance  after monday s release of the replacement plan  hospital stocks fell  with tenet healthcare  thc n  and community health systems  cyh n  each down more than  percent  shares of health insurers were mostly modestly higher  trump s tweet was his latest criticism of drug prices  as president elect  he said in january that the industry was  getting away with murder  in what it charges the government for medicines  he told congress last week that more needs to be done to bring down  artificially high  prices for prescription drugs  while drug stocks have reacted to trump s comments   so far there seems to be no there  there   said ira loss  senior healthcare analyst with washington analysis   loss noted that republicans historically are wary of  non market solutions to drug pricing    i think there is a big disconnect between what he s talking about     and what the natural instincts of a republican controlled congress are   loss said  brad loncar  manager of the loncar cancer immunotherapy etf  cncr o   said trump s comments are  the type of statement that would have sent biotech stocks down  percent six months ago    the fact that hasn t come anywhere near that so far today i think is a good sign the market has learned to wait for specifics on these things and not overreact   loncar said   even tweets have a law of diminishing returns   